AstraZeneca shareholders revolted over executive pay again this year, with 35% having voted against it, including the £9.4 million package for CEO Pascal Soriot. (AstraZeneca) AstraZeneca has made some headway with investors persistently provoked by its executive pay—but not much...
We have made changes to our Remuneration Report in response to feedback, including introducing a simplified bonus structure and enhanced disclosure.
This does indicate the need for the remuneration committee to set more stretching targets within the bonus framework.
The remuneration committee has already engaged with a number of shareholders to understand the reasoning behind their decisions not to support the remuneration report and will continue to engage with shareholders during 2018 to determine how best to address their concerns.
Login to comment.